Article, see p 1371 I n this issue of Circulation, Oliver-Williams and colleagues 1 elegantly demonstrate the relatively low rate of rupture in men with abdominal aortic aneurysms (AAAs) <5.5 cm in diameter. In July 2009, the United Kingdom's National Health Service (NHS) introduced a formal AAA screening program for all men aged >65 years.
Since the inception of this program, the authors have compiled data on 18 652 men with AAA who were either invited for screening or self-referred.
Importantly, only 31 men experienced AAA rupture during the surveillance program, which equated to an incidence of 0.06 per 100 person-years. Death ensued in almost all of these men (29 of 31), which reinforces the well-established notion that elective repair is always preferable to emergent. Maximal aortic diameter was predictive of rupture risk, because the cumulative incidence of rupture over 8 years nearly doubled when small (3-4.4 cm) and medium-sized (4.5-5.4 cm) AAAs were compared (0.35% versus 0.62%, respectively). Still, the annual rate of rupture for medium-sized AAAs was low at 0.4% per year, which suggests that the current threshold for surgical repair (>5.5 cm) is appropriate. Although AAA rupture was a relatively infrequent cause of mortality (3%) in the cohort compared with cancer (31%) or cardiovascular disease (26%), overall mortality rates were ≈60% higher in those men with AAAs who were invited to participate in the surveillance program than in age-and sex-matched control subjects. This finding likely reflects the overall poor health of those with aneurysm disease, who are often smokers with underlying cardiovascular disease.
The purpose of the study by Oliver-Williams et al 1 was not to justify the role of AAA screening in the NHS but rather to ensure that their efforts are in fact safe, especially in those with medium-sized aneurysms. Multiple randomized, controlled trials and meta-analyses have documented the benefit of AAA screening using a single duplex ultrasonography (DU) examination. 3, 4 The most notable trial, which was the basis for the NHS screening program, was the United Kingdom MASS study (Multicentre Aneurysm Screening Study). 3 In this trial, >27 000 men aged 65 to 74 years were screened, and abdominal DU detected >1300 AAAs. At 13 years, the AAA-related mortality was reduced by nearly half in those men invited for screening (0.66%) compared with the control group (1.12%). This reduction equated to an incremental cost-effectiveness ratio of £7600 per life-year gained at 10 years, which compelled the NHS to initiate a formal screening program in 2009. A similar program, albeit slightly more selective, has been implemented in the United States, with AAA screening via DU offered to men aged 65 to 75 years who are active or former smokers. 5 Theoretically, nearly 90% of all AAAs in this age group would be detected if only smokers were examined, hence the more selective screening criteria offered by the US Preventive Services Task Force.
Despite these results supporting the safety and cost-effectiveness of AAA screening, there remains some controversy over its utility. First, one must not overlook the fact that AAA-related mortality is very low. In 2016, fewer than 10 000 people in the United States died of aortic aneurysm disease, which represents only 0.36% of all deaths. 6 In the MASS trial, only 2% of deaths were attributable to AAA. So, the relative risk reduction from screening is tremendous, but the absolute benefits are less impressive. For example, in the MASS study, the overall 10-year mortality in both groups was nearly identical at roughly 30%, and there was no difference in the mean age of death (74.7 years). Furthermore, the US Preventative Services Task Force performed a pooled random effects analysis of all 4 major trials on AAA surveillance, which showed no all-cause mortality benefit.
7 Second, population-based studies have demonstrated a 30% to 50% reduction in AAA-related mortality during the 1990s and 2000s, a period of time preceding screening program implementation. 8 This reduction coincides with an increase in statin therapy and a decrease in tobacco use across these populations. 8, 9 If AAA disease is in fact declining, this would further curtail the absolute benefit from screening protocols and diminish the economic benefit of such programs. Given the decreasing prevalence of disease, in conjunction with data from Oliver-Williams et al 1 revealing the low risk of rupture for medium-sized AAAs, screening programs arguably could garner more cost savings by lengthening the interval at which men undergo DU. Currently in the NHS screening program, men with medium-sized AAAs (4.5-5.4 cm) undergo DU every 3 months. Lengthening the interval to 6 to 12 months for these patients, which would mirror the conclusions offered by the Society for Vascular Surgery, 10 would arguably improve the cost-effectiveness ratio. In fact, a pooled analysis of 18 studies by Bown et al 11 showed that the number of DUs could safely be reduced by 50% by increasing the interval of follow-up to 3 years and 1 year for small (3-3.9 cm) and medium (4.5-5.4 cm) AAAs, respectively, all the while maintaining a risk of rupture below 1%.
Increasing the aortic diameter threshold for which men are recommended to undergo AAA repair is not supported nor investigated in the current study. However, the results from this study suggest that the treatment of medium-sized, asymptomatic AAAs is unnecessary given their low risk of rupture. This sentiment has been expressed in national, international, and societal guidelines, yet clinical practice, especially in countries with a fee-for-service reimbursement system, does not mirror these recommendations, with up to 30% of AAA repairs occurring for aneurysms <5.5 cm. 12 This overutilization of resources adds considerable cost to the healthcare system and is unlikely to increase the overall survival of these patients.
Perhaps as we move forward, a shift away from diameter as the main force dictating AAA repair is needed. Much like carotid stenosis literature focusing on the character of the plaque as opposed to the degree of stenosis, we need to explore alternative, more reliable, and personalized markers of AAA rupture, including circulating biomarkers, magnetic resonance imaginglocalized cellular inflammation, 13 and hemodynamic metrics such as shear stress, flow displacement, or intraluminal thrombus deposition. 14 Finally and perhaps most notably, AAA surveillance, as shown by Oliver-Williams et al 1 in the current report along with the MASS data, does not impact overall survival. This finding is disconcerting and suggests that we are failing our patients by focusing on aneurysm size instead of tobacco cessation, blood pressure control, lipid profile management, and other cardiovascular risk factor modification. In fact, patients in AAA surveillance programs do not improve their cardiovascular risk profile over time. 15 Since the inception of the NHS screening program, >18 000 men have been detected to have AAA, the majority of whom have been compliant with follow-up DU regimens. These office encounters, albeit brief, represent a tremendous opportunity to formally institute secondary preventative measures to reduce their cardiovascular and therefore overall mortality risk. In conclusion, perhaps fewer yet more meaningful visits is the answer to producing a safe and cost-effective AAA screening program that actually improves overall survival.
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